← Eichor
Study identifier: NCT07413562 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Feasibility, Safety, and Preliminary Efficacy of Median Nerve Stimulation for Cognitive Dysfunction in Patients With Acute Traumatic Brain Injury

Condition: Traumatic Brain Injury · Cognitive Dysfunction  ·  Sponsor: Beijing Tiantan Hospital

PhaseNA
Planned participants30
Who can joinAll sexes, 18 Years to 64 Years
Healthy volunteersNo

About this study

Currently, the treatment of cognitive dysfunction after acute TBI remains a challenge, and novel therapeutic methods are urgently needed. Median nerve stimulation (MNS) is a non-invasive neuromodulation technique and recently has shown positive effects in awaking coma of acute brain injury. It has been shown to improve cognition in healthy volunteers and may be a potential therapeutic approach for cognitive dysfunction in patients with acute TBI. Therefore, the main purpose of the study is to evaluate the feasibility, safety, and preliminary efficacy of MNS for cognitive dysfunction in patients with acute TBI.

This description comes directly from the study's public registry record.

Talk to the study team

Liang Wu, MD  ·  18301674233  ·  wuliang@bjtth.org

Yu Deng, MD  ·  15611308032  ·  drdy1998@126.com

Always discuss trial participation with your own doctor first.

Locations (1)

Beijing Tiantan Hospital, Capital Medical UniversityBeijing, Beijing Municipality, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07413562